ReviewFrontiers in pharmacology2026
Kidney angiopoietin-like protein 4 regulates fibrotic responses in diabetic kidney disease.
Review in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Osteoactivin/GPNMB as a candidate biomarker of diabetic nephropathy in type 2 diabetes: associations with angiogenic and kidney injury biomarkers.Frontiers in endocrinology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The angiopoietin-like (ANGPTL) proteins are now recognized as critical regulators of the harmful changes seen in diabetic kidney disease. Notably, a hyposialylated pro-proteinuric form of ANGPTL4 has been identified as a crucial contributor to fibrosis within diabetic kidneys. Under diabetic conditions, glomerular podocytes secrete this hyposialylated ANGPTL4, which plays a significant role in disrupting lipid metabolism, promoting inflammation, and driving fibrosis in both podocytes and adjacent tubules. This secreted ANGPTL4 interacts with tubular cells via Integrin-1 and DPP-4, causing mitochondrial damage that activates the c-GAS-STING pathway and exacerbates inflammation. Importantly, targeting renal ANGPTL4 with antisense oligonucleotides (ASOs) has shown promising protective effects against fibrosis in diabetic kidneys, paving the way for innovative therapeutic strategies to combat diabetic kidney disease and other fibrotic disorders.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.